ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy
May 28, 2020 08:00 ET | ARCA biopharma, Inc.
AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19Previous safety data in more...
Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions
May 07, 2020 08:30 ET | ARCA biopharma, Inc.
New data provide additional evidence of efficacy for Gencaro compared to active control in a pharmacogenetically-defined HF population at risk for AF recurrence °  26% reduction in total time spent...
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update
May 06, 2020 16:30 ET | ARCA biopharma, Inc.
U.S. FDA Special Protocol Assessment agreement for PRECISION-AF, a single pivotal Phase 3 clinical trial of genetically targeted GencaroPRECISION-AF trial to evaluate Gencaro as a potential treatment...
ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update
February 18, 2020 16:30 ET | ARCA biopharma, Inc.
U.S. FDA Special Protocol Assessment agreement for a single pivotal Phase 3 clinical trial (PRECISION-AF) of genetically-targeted GencaroPRECISION-AF clinical trial initiation anticipated fourth...
ARCA Logo - JPEG.jpg
ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium
September 12, 2019 08:30 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 12, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Logo - JPEG.jpg
Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting
September 11, 2019 08:30 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update
August 01, 2019 16:30 ET | ARCA biopharma, Inc.
FDA SPA Agreement for Phase 3 atrial fibrillation trial (PRECISION-AF) amended to expand patient population to include heart failure patients with preserved ejection fraction (HFpEF)PRECISION-AF...
ARCA Logo - JPEG.jpg
ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure
May 13, 2019 09:00 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 13, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Logo - JPEG.jpg
ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 08, 2019 16:30 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 08, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure
May 01, 2019 08:30 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 01, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...